IMHO the rights to be licensed are secondary or even tertiary -- meaning that they are giving up very little. Given the time and money needed, even if CX... whatever gets to the stage to treat neurodegenerative diseases, the big markets (Europe, US/Can and Japan) will account for the predominant share of revs. CORX is in a race against time and financial resources, the faster it can gain any credibility that might some day be monetized the better. I would applaud any deal with Samyang.
Market Data 
Markets 
AI
